MetLife Investment Management’s Soleno Therapeutics SLNO Stock Holding History

MetLife Investment Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-27,501	Closed	-$921K	–	2940
2026 Q1	$921K	Buy	27,501 +1,740	+7%	+$68.2K	﹤0.01%	1443
2025 Q4	$1.19M	Buy	25,761 +1,804	+8%	+$98.9K	0.01%	1325
2025 Q3	$1.62M	Hold	23,957	–	–	0.01%	1203
2025 Q2	$2.01M	Buy	23,957 +8,654	+57%	+$648K	0.01%	987
2025 Q1	$1.09M	Sell	15,303 -236	-2%	-$11.5K	0.01%	1318
2024 Q4	$698K	Buy	15,539 +2,767	+22%	+$143K	﹤0.01%	1609
2024 Q3	$645K	Buy	12,772 +7,196	+129%	+$344K	﹤0.01%	1642
2024 Q2	$228K	Buy	+5,576	New	+$236K	﹤0.01%	2160

MetLife Investment Management's SLNO Position: Q2 2026 in Review

MetLife Investment Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 27,501 shares — an estimated $921K sold.

MetLife Investment Management first reported a position in SLNO in Q2 2024 and held it in 8 quarters. The position peaked at $2.01M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

MetLife Investment Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
MetLife Investment Management sold 27,501 Soleno Therapeutics shares in Q2 2026, an estimated $921K.
MetLife Investment Management first reported a position in Soleno Therapeutics in Q2 2024 and held it in 8 quarters.
MetLife Investment Management's Soleno Therapeutics position peaked at $2.01M in Q2 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.